Source:http://linkedlifedata.com/resource/pubmed/id/18224319
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2008-3-20
|
| pubmed:abstractText |
The proof of concept for in vivo targeting of beta-amyloid plaques (Abeta) in patients with Alzheimer's disease (AD) by means of nuclear imaging methods has been shown in recent clinical studies.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1619-7070
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
35 Suppl 1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S75-81
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading | |
| pubmed:year |
2008
|
| pubmed:articleTitle |
Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography.
|
| pubmed:affiliation |
Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, München, Germany. G.Henriksen@lrz.tum.de
|
| pubmed:publicationType |
Journal Article,
Review
|